Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Gabutti, Luca ^a   Nobile, Filippo ^a   Forni, Valentina ^b   Rigamonti, Fabio ^a   Weibel, Nadir ^c   Burnier, Michel ^b  

^a Ospedale la Carit   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ARTICLE; BLEEDING; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG HALF LIFE; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; FEASIBILITY STUDY; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRESCRIPTION; SIMULATION; SIMULATOR; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG EFFECT;

COMPUTER SIMULATION; ERYTHROPOIETIN; FEASIBILITY STUDIES; HEMOGLOBINS; HUMANS; MODELS, BIOLOGICAL; PRESCRIPTIONS;

EID: 79951559712     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-11     Document Type: Article

References (33)

1. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. CE Halstenson M Macres SA Katz JR Schnieders M Watanabe JT Sobota PA Abraham, Clin Pharmacol Ther 1991 50 702 712 10.1038/clpt.1991.210 1752115
2. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. IC Macdougall SJ Gray O Elston C Breen B Jenkins J Browne J Egrie, J Am Soc Nephrol 1999 10 2392 2395 10541299 (Pubitemid 29501473)
3. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. IC Macdougall, Nephrol Dial Transplant 2002 17 66 70 10.1093/ndt/17.suppl-5.66 12091611
4. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. IC Macdougall R Robson S Opatrna X Liogier A Pannier P Jordan FC Dougherty B Reigner, Clin J Am Soc Nephrol 2006 1 1211 1215 10.2215/CJN.00730306 17699350
5. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. IC Macdougall, Curr Hematol Rep 2005 4 436 440 16232379
6. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. R Minutolo P Chiodini B Cianciaruso A Pota V Bellizzi D Avino S Mascia S Laurino V Bertino G Conte L De Nicola, Clin J Am Soc Nephrol 2009 4 552 559 10.2215/CJN.04380808 19261821
7. Hemoglobin level variability in renal transplant patients treated with erythropoiesis stimulating agents. G Fernndez Fresnedo AL De Francisco JC Ruiz C Gámez Alamillo M Arias, Transplant Proc 2008 40 2919 2921 19010147
8. Factors affecting anemia management in hemodialysis patients: a single-center experience. DM Spiegel M Gitlin T Mayne, Hemodial Int 2008 12 336 341 10.1111/j.1542-4758.2008.00278.x 18638090
9. Insights in anemia management. AL De Francisco C Pĩera, Hemodial Int 2008 12 336 341 10.1111/j.1542-4758.2008.00278.x 18638090
10. Frequent assessment of longitudinal laboratory trends: a key to minimizing hemoglobin variability in patients on dialysis. D Brooks, Nephrol Nurs J 2007 34 435 439 17891912
11. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa. R Walker BA Pussel Australian Renal Anaemia Group, Nephrology (Carlton) 2007 12 448 451 10.1111/j.1440-1797.2007.00802.x 17803467 (Pubitemid 47366636)
12. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. JP Ebben DT Gilbertson RN Foley AJ Collins, Clin J Am Soc Nephrol 2006 1 1205 1210 10.2215/CJN.01110306 17699349
13. Hemoglobin variability in patients with chronic renal insufficiency. G Deray, Nephrol Ther 2008 4 549 552 19004677
14. Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. W Krzyzanski JJ Perez-Ruixo A Vermeulen, J Pharmacokinet Pharmacodyn 2008 35 349 377 10.1007/s10928-008-9092-6 18551354
15. Pharmacodynamic analysis of recombinant human erythropietin effect on reticulocyte production rate and age distribution in healthy subjects. JJ Pérez-Ruixo W Krzyanski J Hing, Clin Pharmacokinet 2008 47 399 415 18479174 (Pubitemid 351685389)
16. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. T McGowan NM Vaccaro JS Beaver J Massarella M Wolfson, Clin J Am Soc Nephrol 2008 3 1006 1014 10.2215/CJN.05671207 18417741
17. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). S Woo W Krzyzanski WJ Jusko, J Pharmacokinet Pharmacodyn 2007 34 849 868 10.1007/s10928-007-9074-0 17943422 (Pubitemid 350165278)
18. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. W Krzyzanski JJ Perez-Ruixo, Pharm Res 2007 24 758 772 10.1007/s11095-006-9195-y 17318417 (Pubitemid 46411964)
19. Hemoglobin cycling in hemodialysis patients treated with recombinatn human erythropoietin. S Fishbane JS Berns, Kidney Int 2005 68 1337 1343 10.1111/j.1523-1755.2005.00532.x 16105069 (Pubitemid 43246455)
20. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. AK Singh E Milford S Fishbane SR Keithi-Reddy, Kidney Int 2008 74 679 683 10.1038/ki.2008.59 18337717
21. Evidence and implications of haemoglobin cycling in anemia management. S Fishbane JS Berns, Nephro Dial Transplant 2007 22 2129 2132 10.1093/ndt/gfm384 (Pubitemid 47244687)
22. Hemoglobin Variability and Mortality in ESRD. W Yang RK Israni SM Brunelli MM Joffe S Fishbane HI Feldman, J Am Soc Nephrol 2007 18 3164 3170 10.1681/ASN.2007010058 18003781 (Pubitemid 350223976)
23. Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness? L Gabutti N Lötscher J Bianda C Marone G Mombelli M Burnier, BMC Nephrol 2006 7 13 10.1186/1471-2369-7- 13 16981983
24. Hemoglobin variability in epoetin-treated hemodialysis patients. JS Berns H Elzein RI Lynn S Fishbane IS Meisels PB Deoreo, Kidney International 2003 64 1514 1521 10.1046/j.1523-1755.2003.00229.x 12969173 (Pubitemid 37153820)
25. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). F Locatelli A Covic KU Eckardt A Wiecek R Vanholder ERA-EDTA ERBP Advisory Board, Nephrol Dial Transplant 2009 24 2288 10.1093/ndt/gfp202
26. Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. FK Port RL Pisoni J Bommer F Locatelli M Jadoul G Eknoyan K Kurokawa BJ Canaud MP Finley EW Young, Clin J Am Soc Nephrol 2006 1 246 255 10.2215/CJN.01050905 17699213
27. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. DE Uehlinger FA Gotch LB Sheiner, 1992 51 76 89 1732079
28. Pharmacodynamic Analysis of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects. JJ Pérez-Ruixo W Krzyzanski J Hing, Clin. Pharmacokinet 2008 47 399 415 18479174 (Pubitemid 351685389)
29. An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy Subjects. W Krzyzanski JJ Pérez-Ruixo, Pharmaceutical Research 2007 24 758 772 10.1007/s11095-006- 9195-y 17318417 (Pubitemid 46411964)
30. Flow Cytometric Analysis of Reticulocyte Maturation After Erythropoietin Administration in Rats. P Wiczling S Ait-Oudhia W Krzyzanski, Cytometry A 2009 75 584 592 19437531
31. Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers. R Ramakrishnan WK Cheung MC Wacholtz N Minton WJ Jusko, J Clin Pharmacol 2004 44 991 1002 10.1177/0091270004268411 15317827 (Pubitemid 39096814)
32. Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting. M Pradella I Cavill G D'Onofrio, Clin Lab Haematol 1996 18 35 37 9054717
33. Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. TJ Arneson D Zaun Y Peng CA Solid S Dunning DT Gilbertson, Nephrology Dialysis Transplantation 2009 24 1378 1383 10.1093/ndt/gfp018